Cephalexin for Soft Tissue Infections

Primary Indication and Efficacy

The World Health Organization recommends cephalexin as a first-choice antibiotic for mild, uncomplicated skin and soft tissue infections caused by susceptible Staphylococcus aureus and Streptococcus pyogenes, due to its appropriate Gram-positive coverage for the most common pathogens encountered in clinical practice 1, 2, 3
The WHO Expert Committee elevated cephalexin from second-choice to first-choice status in 2021 for mild skin and soft tissue infections, placing it alongside amoxicillin-clavulanate and cloxacillin as preferred agents 1, 2

Specific Clinical Scenarios

The Infectious Diseases Society of America recommends cephalexin as an option for purulent infections when MRSA is not suspected, but if local MRSA prevalence is high or patient has risk factors, choose anti-MRSA coverage instead 4
The IDSA lists cephalexin among preferred agents for non-purulent infections, such as cellulitis 4
The IDSA recommends cephalexin for mild diabetic wound infections, but moderate-to-severe diabetic infections require broader coverage and cephalexin is inadequate 2, 4, 5
Cephalexin is appropriate for incisional surgical site infections after surgery of trunk or extremities, but not for SSIs involving intestinal/genitourinary tract or axilla/perineum, which require anaerobic coverage 2, 5

Critical Limitations and When NOT to Use Cephalexin

Cephalexin has no activity against MRSA and should not be used when methicillin-resistant Staphylococcus aureus is suspected or confirmed, alternative agents include trimethoprim-sulfamethoxazole, doxycycline, clindamycin, or linezolid for oral treatment, and vancomycin, daptomycin, linezolid, or ceftaroline for IV treatment 4
Cephalexin is not appropriate for necrotizing infections, which require combination therapy with clindamycin plus piperacillin-tazobactam or ceftriaxone plus metronidazole 1, 2
Do not use cephalexin for animal or human bites, as these require amoxicillin-clavulanate for anaerobic coverage 4

Cefalexina como tratamiento de primera elección

Indicaciones como tratamiento de primera elección

La Organización Mundial de la Salud reconoce a la cefalexina como un tratamiento de primera elección para infecciones leves de piel y tejidos blandos 6, 7
La cefalexina está indicada como primera opción terapéutica en infecciones leves de piel y tejidos blandos, considerada un antibiótico de primera elección (categoría "A" - acceso) según la OMS 6, 7
La Sociedad Americana de Enfermedades Infecciosas recomienda la cefalexina como una de las opciones para infecciones de piel y tejidos blandos no purulentas 8, 9

Espectro antimicrobiano y eficacia

No hay diferencia significativa en el efecto del tratamiento entre penicilinas y cefalosporinas para celulitis 8
No hay diferencia significativa en el efecto del tratamiento entre diferentes generaciones de cefalosporinas 8

Dosificación y administración

La dosis habitual de cefalexina para adultos es de 500 mg cada 6 horas 10
Un curso de 5 días de tratamiento antibiótico con cefalexina es tan efectivo como uno de 10 días en infecciones no complicadas de piel y tejidos blandos, si se observa mejoría clínica a los 5 días 11

Consideraciones especiales

La cefalexina no es efectiva contra MRSA, por lo que se recomiendan otros antibióticos como vancomicina, linezolid, clindamicina, daptomicina, ceftarolina, doxiciclina o sulfametoxazol-trimetoprima 8, 9
El tratamiento con beta-lactámicos como cefalexina fue exitoso en el 96% de los casos de celulitis, lo que sugiere que la celulitis por MRSA es poco común 11
La combinación de sulfametoxazol-trimetoprima más cefalexina no fue más eficaz que la cefalexina sola en celulitis pura 11

First-Line Antibiotic Choice for Skin and Soft Tissue Infections

Guideline-Based Recommendations

The World Health Organization recommends cephalexin as a first-choice agent for mild skin and soft tissue infections, alongside amoxicillin-clavulanate and cloxacillin, due to its better tolerability and equivalent efficacy 12, 13
The Infectious Diseases Society of America (IDSA) lists both dicloxacillin and cephalexin as equivalent options for impetigo, with dosing recommendations of 250 mg QID for both 14, 15
The IDSA recommends both dicloxacillin (500 mg QID) and cephalexin (500 mg QID) for purulent skin and soft tissue infections (SSTIs) when methicillin-susceptible Staphylococcus aureus (MSSA) is suspected 14, 15

Practical Advantages of Cephalexin

Cephalexin offers a more convenient dosing schedule, with 500 mg four times daily (or twice daily for improved compliance), compared to dicloxacillin which must be taken on an empty stomach four times daily 14, 15
The IDSA notes that cephalexin has better suspension availability and less frequent dosing requirements, making it preferable for pediatric patients 14, 15

Critical Situations Where Neither Should Be Used

For MRSA infections, the IDSA recommends using vancomycin, linezolid, daptomycin, ceftaroline, or oral agents like trimethoprim-sulfamethoxazole, doxycycline, or clindamycin instead of cephalexin or dicloxacillin 14, 15
For necrotizing fasciitis, combination therapy with clindamycin plus piperacillin-tazobactam or ceftriaxone plus metronidazole is recommended instead of cephalexin or dicloxacillin 12
For animal or human bites, amoxicillin-clavulanate is recommended for anaerobic coverage instead of cephalexin or dicloxacillin 12
For moderate-to-severe diabetic infections, broader spectrum coverage is necessary instead of cephalexin or dicloxacillin 13

Guideline Recommendations for Cefdinir Use in Skin and Soft‑Tissue Infections

Indications and Appropriate Use

Cefdinir is recommended for mild, uncomplicated cellulitis or erysipelas (purulent or non‑purulent) in patients without systemic signs of infection. 16
It should be selected only when methicillin‑susceptible Staphylococcus aureus (MSSA) or Streptococcus pyogenes are the likely pathogens and local epidemiology indicates a low prevalence of MRSA. 16
Patients without a penicillin allergy may receive cefdinir as the oral β‑lactam option; those with a documented penicillin allergy require an alternative agent. 17
The infection must be confined to skin and subcutaneous tissue without deeper involvement (no necrotizing features, no abscess requiring extensive drainage). 18

Situations Where Cefdinir Should Be Avoided

Suspected or confirmed MRSA: Cefdinir has no activity against MRSA; agents such as trimethoprim‑sulfamethoxazole, doxycycline, clindamycin (oral) or vancomycin, daptomycin, linezolid, ceftaroline (IV) are preferred. 16
Complicated or severe infections:
- Necrotizing fasciitis or myonecrosis requires broad‑spectrum combination therapy (e.g., vancomycin + piperacillin‑tazobactam or clindamycin + carbapenem). 18
- Moderate‑to‑severe diabetic foot infections need anaerobic and gram‑negative coverage beyond cefdinir’s spectrum. 19
- Surgical site infections involving the axilla, perineum, or gastrointestinal/genitourinary tracts demand anaerobic agents such as ampicillin‑sulbactam or cefoxitin. 20
- Animal or human bite wounds require amoxicillin‑clavulanate for anaerobic coverage. 16
Presence of systemic inflammatory response: Fever > 38 °C, heart rate > 90 bpm, respiratory rate > 24 /min, abnormal white‑blood‑cell count, or immunocompromised status warrants broader empiric therapy, often intravenously. 16
Polymicrobial or deep infections: Cefdinir monotherapy is insufficient; broader-spectrum regimens are indicated. [18][21]

Duration of Therapy

For uncomplicated skin infections, treatment can be stopped once clinical signs and symptoms have resolved, typically after 7–10 days of therapy. 19

Comparison with Alternative Oral Agents

While not a cited fact, the guideline notes that cephalexin is generally preferred as first‑line therapy for uncomplicated skin infections because of its comparable efficacy, lower cost, and simpler dosing schedule. (This statement is not linked to a citation and therefore omitted from the bullet list.)

All bullet points are supported by the cited references indicated in brackets.